Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00180479 · ClinicalTrials.gov registry record · Phase 3
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
A Phase 3 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,002
- Enrollment target
NCT00180479 is a Phase 3 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,002 participants.
The verdict
NCT00180479, a Phase 3 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,002 participants
- Enrollment target
Study Summary
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stents) to the Food and Drug Administration (FDA) approved commercially available active control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS) System 2. US 2.25 mm non-randomized arm using 2.25 mm diameter XIENCE V® Everolimus Eluting CSS 3. US 4.0 mm non-randomized arm using 4.0 mm diameter XIENCE V® Everolimus Eluting CSS 4. US 38 mm non-randomized arm using 38 mm in length XIENCE V® Everolimus Eluting CSS 5. Japanese non-randomized arm using XIENCE V® Everolimus Eluting CSS (2.5, 3.0, 3.5, 4.0 mm diameter stents) in Japan The TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is Manufactured by Boston Scientific.
Interventions
- DEVICE XIENCE V® Everolimus Eluting Coronary Stent
- DEVICE TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2005-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00180479
The ClinicalTrials.gov registry entry for NCT00180479 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,002 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE V® Everolimus Eluting Coronary Stent is the first listed.
NCT00180479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00180479 about?
NCT00180479 is a clinical study titled "SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)". This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stent...
What is the current status of trial NCT00180479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,002 participants. The study started on 2005-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00180479?
The interventions under investigation include: XIENCE V® Everolimus Eluting Coronary Stent (DEVICE), TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00180479?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.